Alembic Pharmaceuticals Ltd vs Brooks Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 759.95 as of 04 May 09:18 . The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 16.5 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 13.66% over 5 yearsThe P/E Ratio of Brooks Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 18971 crore on March 2021 to ₹ 18265 crore on March 2025 . This represents a CAGR of -0.76% over 5 yearsThe Market Cap of Brooks Laboratories Ltd changed from ₹ 153.53 crore on March 2021 to ₹ 317.37 crore on March 2025 . This represents a CAGR of 15.63% over 5 years The revenue of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 1891 crore as compare to the Sep '25 revenue of ₹ 1918 crore. This represent the decline of -1.39% The revenue of Brooks Laboratories Ltd for the Dec '25 is ₹ 21.89 crore as compare to the Sep '25 revenue of ₹ 29.58 crore. This represent the decline of -26% The ebitda of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 264.93 crore as compare to the Sep '25 ebitda of ₹ 324.02 crore. This represent the decline of -18.24% The ebitda of Brooks Laboratories Ltd for the Dec '25 is ₹ 6.05 crore as compare to the Sep '25 ebitda of ₹ 8.65 crore. This represent the decline of -30.06% The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 134.54 crore to ₹ 131.95 crore over 7 quarters. This represents a CAGR of -1.10% The net profit of Brooks Laboratories Ltd changed from ₹ -2.41 crore to ₹ 5.5 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 25.09 % on March 2021 to 42.97 % on March 2025 . This represents a CAGR of 11.36% over 5 yearsThe Dividend Payout of Brooks Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
The company is engaged in pharmaceuticals business.
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Brooks Laboratories Ltd

Brooks Laboratories Limited was incorporated on January 23, 2002.
The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers.
The Company is a pharmaceutical manufacturing company working on contract basis and have its own marketing team to cater the critical care segment.
It offer a variety of dosage from Beta lactam Tablets, Beta lactam Dry Syrup, General Injections, Liquid Injections, Dry Powder Injections, and Eye/Ear Drops, Oncology Products, Hormonal Injections etc. The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes.
At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Brooks Laboratories Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Brooks Laboratories Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 14,830 Cr while Market cap of Brooks Laboratories Ltd is 166 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Brooks Laboratories Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Brooks Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Brooks Laboratories Ltd?

As of May 4, 2026, the Alembic Pharmaceuticals Ltd stock price is INR ₹754.5. On the other hand, Brooks Laboratories Ltd stock price is INR ₹56.48.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Brooks Laboratories Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Brooks Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.